linjc16/ctgov huggingface dataset:
Longitudinal MRI Examinations of Patients With Brain Ischemia and Blood Brain Barrier Permeability

Study Overview
=================
Brief Summary
-----------------
The objective of this trial is to visualize blood brain barrier function and metabolic changes in the first days after ischemic stroke with new investigational MRI sequences.

Detailed Description
-----------------
In this study the investigators will be examining acute ischemic stroke patients on the first and second day after symptom onset using repetitive MRI examinations to visualize blood brain barrier function and metabolic changes of the brain in 5 sub-projects, each containing a specific MRI protocol with one of the following new MRI sequences: T1-Dynamics (measuring disruptions of the blood-brain barrier) pH-imaging (measuring metabolic changes, acidosis) Resting-state MRI (measuring changes in the cerebral perfusion) Quantitative MRI-Angiography (quantification of blood flow in single vessels) Diffusion Tensor Imaging (DTI) for patients with Anterior Choroidal Artery (AChA)-Infarcts (quantification of damage of white matter tracts) Each sub-projects will be conducted in blocks of a specific time span. Morphological outcome will be assessed at day 5-7. Clinical outcome will be assessed at day 5-7 and day 90. The association of the new imaging parameter with the clinical and morphological outcome measures will be analysed. No specific intervention is assigned to the subjects by the investigators of the study.

Official Title
-----------------
Longitudinal Observation of Brain Ischemia and Blood Brain Barrier Permeability in the Acute Phase of Ischemic Stroke

Conditions
-----------------
Cerebral Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected stroke or transient ischemic attack (TIA) within 24h from symptom onset Exclusion Criteria: MRI contraindication, age < 18 years, intracranial hemorrhages

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical outcome measured with the National Institutes of Health Stroke Scale (NIHSS) |  | on follow-up examination day 5-7 | 
| clinical outcome measured with the modified Rankin Scale (mRS) | conducted as telephone interview | on day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| final lesion volume (measured on FLAIR images) |  | on follow-up examination day 5-7 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute ischemic stroke
Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting

Study Overview
=================
Brief Summary
-----------------
The primary objective of this research project is to estimate the number of patients with sarcoma or melanoma attending an outpatients clinic that are in pain or have unmet pain needs.

Official Title
-----------------
Pain Prevalence and Risk Factors Amongst Sarcoma/Melanoma Oncology Outpatients. A Baseline, Cross Sectional Study Towards a Pain Free Hospital

Conditions
-----------------
Sarcoma, Melanoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of sarcoma or melanoma cancer Able to respond to an assessment in written English. Able to provide informed consent to participate in the study. Exclusion Criteria: Patients whose health would be compromised by participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients with significant pain and the proportion of patients with a negative score on the pain management index (PMI) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with neuropathic pain. |  |  | 
| Potential predictors of pain. The variables tested as potential risk factors will be age, tumour type, gender and treatment type. |  |  | 
| We will also seek to identify potential predictors of pain intensity in patients that do have pain. In addition to the risk factors already mentioned above, duration and cause of pain will also be tested in this case as potential pain predictors. |  |  |
Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology

Study Overview
=================
Brief Summary
-----------------
The goals of this study are to assess the feasibility of weekly administration of site specific patient reported assessments using an electronic platform and to explore the correlation between patient reported outcomes as well as known dosimetric prognostic factors in patients with lung, breast, head and neck, or pelvic malignancies

Official Title
-----------------
Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology

Conditions
-----------------
Patients With Lung, Breast, Head and Neck, or Pelvic Malignancies

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with breast cancer, lung cancer, head and neck cancer, or gynecologic cancer receiving definitive external beam radiotherapy. Must be ≥ 18 years of age Able to read, write, and speak English in order to complete patient reported outcomes. Patients will be approached about the study at the time of consultation or at the time of simulation by their treating physicians or by a research coordinator. All patients must sign a study-specific informed consent to participate. All patients, including those who do not choose to consent to the study, will be provided with a short survey to assess health literacy using the eHealth Literacy Scale (eHEALS). For those not consenting to the study, the survey will be de-identified and will also ask for basic demographic information including age grouping, race, education level, and type of cancer.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Completed subjects<br>Subjects will complete patient-reported outcomes assessments during and after radiation therapy. | Other: Survey<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Surveys completed |  | five years |
Circadian Rhythm of Melatonin in Burns

Study Overview
=================
Brief Summary
-----------------
Evaluate markers and postulated effectors of the endogenous circadian pacemaker in children admitted to the burn intensive care unit.

Official Title
-----------------
Role of Circadian Rhythm of Melatonin on Sleep-related Disturbances Postburn

Conditions
-----------------
Sleep, Burns

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 5-18 years old Exclusion Criteria: anoxic brain injury preexisting neurological disorder pre-existing sleep disorder no informed consent or HIPAA release

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acute burns<br> | |
| rehab patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sleep status | actigraphy, polysomnography | 48hrs | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urinary melatonin |  | every 2 hours for 48 hrs |
Transcranial and Rapid Magnetic Stimulation for Gait Apraxia Due to Normal Pressure Hydrocephalus and Cerebral Ischemia

Study Overview
=================
Brief Summary
-----------------
The investigator(neurologist) has published a study in International Congress Series, in the 15th International Conference of Biomagnetism Vancouver Proceedings 2006,and Science Direct website, of 15 patients with brain ischemia and dilated ventricles who improve when treated with transcranial monitoring or low ultrasound wave intensity (milliwatts) and with rapid magnetic stimulation which is also a diagnostic tool routinely used by many neurophysiologists. Before, these patients will progress and may need a brain shunt called Ventriculo-peritoneal shunt. He and collaborators now would like to do a double study as this appears to be a cheap and effective alternative treatment and help patients to walk again.

Detailed Description
-----------------
The transcranial monitoring intensity would be equivalent to the well known CLOTBUST study (<300mw/sq cm)for one hour, using two probes. All will be treated as an outpatient and there is no form of infusion or interventional treatment. The rapid magnetic stimulation is at about 50a/us, 15Hz, 1000 pulses with 10 sec pause for ten days along the skull vault. Informed consent will be obtained. 30 patients will be recruited and sham treatment would be just applying probe without power for transcranial and for magnetic stimulation coil will be angled away. Data will be compiled by a separate blinded investigator and so with the statistics. VP shunt failure patients, which is common, will be included. Barthel's daily living index and standard cognitive tests will be used to assess results.

Conditions
-----------------
Walking, Cognitive Function

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cerebral ischemia with our without hydrocephalus and gait apraxia Exclusion Criteria: all other conditions which contribute to walking difficulty e.g. bad knees; or spondylosis; parkinson's or paralytic strokes
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transcranial sonolysis or monitoring, rapid magnetic stimulation, cerebral ischemia, hydrocephalus, Barthel's index
Effect of Liver MSCs in Blood of Patients With Liver Disease.

Study Overview
=================
Brief Summary
-----------------
Liver MSCs or Adult Derived Human Liver Stem/progenitor Cells (ADHLSCs) infusions are currently being developed as a therapeutic medicinal product for the treatment of different liver defects. Nevertheless, a main concern for clinicians and health authorities is the risk of therapy-induced thrombosis, which has been reported in several patients after intravenous infusion. Previous studies showed in fact that most MSCs express a procoagulant activity. ADHLSCs could be used to treat acute de-compensated cirrhotic patients due to their immunomodulatory and anti-fibrotic effects. However in these patients, disturbances of coagulation and haemostasis are common and result in profound haemostatic alterations that can lead to thrombosis as well as to bleeding complications. The aim of this study is to evaluate the effect of ADHLSCs in cirrhotic blood compared to control blood.

Official Title
-----------------
In Vitro Evaluation of the Effect of HepaStem in the Coagulation Activity in Blood of Patients With Liver Disease.

Conditions
-----------------
Decompensated Cirrhosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute de-compensated cirrhotic patients Exclusion Criteria: anticoagulant treatment except for prophylactic heparin treatment coagulopathy thrombosis cancer

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood parameters in tubing loop model | We plan to use the tubing loop model to study the interaction between acute-on-chronic liver failure patient's blood and ADHLSCss. The tubing loop model is a whole blood coagulation in vitro model that mimics the blood flow circulation. It consists of loops made of polyvinyl chloride tubing coated with heparin without any release of heparin in blood. This technique can be used to mimic cell infusion in an in vitro model as close as possible to a patient infusion. Blood parameters are studied after 5 and 60min incubation. | 1 day | 
| Fibrin formation in thrombodynamics | The thrombodynamics analyser system records and analyses spatiotemporal dynamics of formation of a fibrin clot in a platelet poor plasma (PPP) sample. We plan to use this model to study the interaction between acute-on-chronic liver failure patient's plasma and ADHLSCss. | 1 day |
Efficacy and Safety of Shinbaro Capsule

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of 'Shinbaro Capsule', a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee.

Official Title
-----------------
A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Shinbaro Capsule
* Drug: Celebrex


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 35 and 80 diagnosed with Knee OA based on criteria of ACR and showed ont through I   III of Kellgren Stage on radiography wuffered constantly with Knee OA for more than 6 months prior to begining the study scored more than 30 on total WOMAC scale Exclusion Criteria: had other comorbid orthopedic disease had OA of index knee from significant trauma or surgery

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GCSB<br> | Drug: Shinbaro Capsule<br>* Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)<br>|
| Active Comparator: Celebrex<br> | Drug: Celebrex<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC change | WOMAC change | Baseline, 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 100mm Pain VAS on walking | change, percent change | Baseline, 12 weeks | 
| PGART |  | 12 weeks | 
| Adverse Events |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoarthritis
Evaluation of Perioperative Management of Curative Anticoagulants in the Geriatric Perioperative Unit in Patient Hospitalized for Femoral Neck Fracture.

Study Overview
=================
Brief Summary
-----------------
Pilot study to evaluate the management of curative anticoagulant prescriptions pre- and postoperatively in elderly patients hospitalized for femoral neck fracture.

Official Title
-----------------
Evaluation of Perioperative Management of Curative Anticoagulants in the Geriatric Perioperative Unit in Patient Hospitalized for Femoral Neck Fracture.

Conditions
-----------------
Anticoagulants; Circulating, Hemorrhagic Disorder, Femoral Neck Fractures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient 75 years or older Hospitalized in the geriatric perioperative unit for a femoral neck fracture between 18/11/2019 and 30/06/2021 Treated with a curative anticoagulant at entry Patient enrolled in or receiving a social security plan Exclusion Criteria: Orthopedic patient housed in the geriatric perioperative unit Patient who objected to the use of their data

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of compliance with the recommendations for direct oral anticoagulants (DOAC).. | Rate of compliance with the french working group on perioperative haemostasis (GIHP) recommendations for DOACrecommendations for DOA. | Day 0 | 
| Rate of compliance with the recommendations for vitamin K antagonists (VKA). | Rate of compliance with the french health authority (HAS) recommendations for VKA | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of pharmaceutical interventions | Number of pharmaceutical interventions regarding anticoagulant prescriptions | Day 0 | 
| description of pharmaceutical interventions | description of pharmaceutical interventions | Day 0 | 
| Evaluation of the morbi-mortality | Mortality, re-hospitalizations at 30 days, characterization of bleeding complications, characterization of thrombotic complications | Day 0 | 
| Description of the evolution of the plasma dosage of DOAC and the international normalized ratio (INR) and analysis of the operative delay | Value of preoperative DOAC plasma dosage, value of INR dosage pre- and post-op, analysis of the operative delay | Day 0 | 
| description of the population | age, weight, height, body mass index, comorbidities | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
older patients, anticoagulant, femoral neck fractures, clinical pharmacy service
Impact of Patient Education on Influenza Vaccine Uptake Among Community-dwelling Chinese Elderly

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the effectiveness of brief face-to-face patient education in increasing uptake of influenza vaccine among Chinese elderly in the community.

Official Title
-----------------
Impact of Patient Education on Influenza Vaccine Uptake Among Community-dwelling Chinese Elderly: A Randomised Controlled Trial

Conditions
-----------------
Influenza, Human

Intervention / Treatment
-----------------
* Behavioral: Patient Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cantonese speaking Chinese Exclusion Criteria: cognitively impaired unable to communicate effectively having known contraindication of vaccination institutionalized

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient Education<br> | Behavioral: Patient Education<br> <br> |
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proportion of patients receiving influenza vaccination |  | three working days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proportion of patients receiving influenza vaccination |  | five working days | 
| proportion of patients receiving influenza vaccination |  | seven working days | 
| proportion of patients receiving influenza vaccination |  | nine working days |